Zelira Therapeutics has announced the University of Western Australia team that undertook a double-blind, placebo-controlled, crossover trial of its ZTL-101 (Zenivol) treatment for chronic insomnia patients has had the results published in peer-reviewed journal Sleep.

The results of the trial, undertaken at the university’s Centre for Sleep Science and published earlier this year, showed patients saw a significant decrease in insomnia after using Zenivol for two weeks relative to a placebo. Chronic insomnia is present in six to 15% of the population.

Chronic insomnia is present in six to 15% of the population.

Zenivol was launched in Australia in September last year and is available through the TGA’s Special Access and Authorised Prescriber Schemes.

Zelira CEO Dr Oludare Odumosu said: “Physicians and patients often ask for published, peer-reviewed data from a double-blind, placebo-controlled, crossover study.

“With this publication… we can confidently say ‘here you have the first scientific peer reviewed publication for a cannabinoid medicine to treat insomnia’.”

“Zelira is committed to taking Zenivol through registration approval as the world’s first fully validated and approved cannabinoid treatment for chronic insomnia.”